Who makes IIV4+PPV23?

IIV4+PPV23 is developed by China National Biotec Group Company Limited.

What development phase is IIV4+PPV23 in?

IIV4+PPV23 is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

IIV4+PPV23

China National Biotec Group Company Limited · FDA-approved active Biologic Quality 4/100

At a glance

Generic name	IIV4+PPV23
Sponsor	China National Biotec Group Company Limited
Modality	Biologic
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population (PHASE4)
Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4 (PHASE4)
Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4 (PHASE4)
Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4 (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IIV4+PPV23 CI brief — competitive landscape report
IIV4+PPV23 updates RSS · CI watch RSS
China National Biotec Group Company Limited portfolio CI